unknown
Stage
2
Investors
About
Yarrow Biosciences is developing a first-in-class anti-TSHR antibody aimed at treating Graves’ disease and thyroid eye disease.
Explore Yarrow Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.